title: New developments in heart failure: role of endothelin and the use of endothelin receptor antagonists.
abstract: Despite conventional therapy, there is still much room for improvement in the prognosis of patients with chronic systolic heart failure. Evidence supports a role for endothelin-1 (ET-1), a potent vasoconstrictor, in the pathophysiology of heart failure. Given its potentially deleterious effects, the optimal treatment of heart failure may need to include efforts directed toward antagonizing this hormone. In support of this notion, the use of ET receptor antagonists produces a number of beneficial effects in heart failure, including both improvements in hemodynamics and reductions in the levels of other vasoconstricting neurohormones. There are at least 2 receptors for ET-1 (the ET-A and ET-B receptor), and the effects of ET-1 binding differ depending on the receptor involved. It is still unclear whether blockade of the ET-A receptor alone or the combined blockade of both the ET-A and ET-B receptors will be most efficacious as a therapeutic strategy. Long-term benefits have been achieved with the use of a mixed ET-A/B receptor antagonist, when added to standard triple-drug therapy, in patients with severe heart failure. We await the results of ongoing trials to determine if these agents will fulfill the promise of adding substantial incremental benefit to the treatment of the disease.
authors.affiliation: Division of Cardiology, University of Cincinnati College of Medicine, Ohio, USA.
authors.forename: D P
authors.initials: DP
authors.lastname: Suresh
authors.forename: S
authors.initials: S
authors.lastname: Lamba
authors.forename: W T
authors.initials: WT
authors.lastname: Abraham
mesh_terms: D000077300:Bosentan; D002264:Carboxylic Acids / Q000494:pharmacology / Q000627:therapeutic use; D002908:Chronic Disease; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000502:physiology*; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D007189:Indans / Q000494:pharmacology / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000494:pharmacology / Q000627:therapeutic use; D011379:Prognosis; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D017466:Receptors, Endothelin / Q000145:classification; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D002264:Carboxylic Acids; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D007189:Indans; D010456:Peptides, Cyclic; D011725:Pyridines; D011743:Pyrimidines; D017466:Receptors, Endothelin; D013449:Sulfonamides; C113972:T 0201; C119319:J 104132; D000077300:Bosentan; C098288:enrasentan; C072247:cyclo(Trp-Asp-Pro-Val-Leu)